Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Agios Pharmaceuticals, Inc. - Common Stock
(NQ:
AGIO
)
27.77
-0.44 (-1.56%)
Streaming Delayed Price
Updated: 3:36 PM EDT, May 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Agios Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
↗
May 02, 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
↗
April 16, 2024
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.
Via
InvestorPlace
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
↗
February 23, 2024
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Via
Investor's Business Daily
Earnings Scheduled For February 15, 2024
↗
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Earnings Preview: Agios Pharmaceuticals
↗
February 14, 2024
Via
Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
↗
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
↗
June 27, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
↗
May 15, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Insights
↗
February 24, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
↗
November 17, 2022
Via
Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
↗
August 15, 2022
Via
Benzinga
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
↗
January 03, 2024
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary
Via
Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
↗
January 03, 2024
The company is working on an oral treatment for alpha and beta thalassemia.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 03, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
January 03, 2024
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!
Via
InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
↗
June 26, 2023
Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its
Via
Benzinga
Why Shares of Schrödinger Rose This Week
↗
June 16, 2023
Interest in the company's AI platform continues to drive the stock.
Via
The Motley Fool
7 Biotech Stocks to Buy for 100% Returns
↗
April 09, 2023
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
Via
InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
↗
March 15, 2023
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
↗
February 03, 2023
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
↗
December 24, 2022
The attraction of all three biotech stocks is their potential.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
↗
November 17, 2022
Upgrades
Via
Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
↗
November 11, 2022
Via
Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
↗
November 03, 2022
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
↗
September 02, 2022
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.
Via
Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
↗
September 01, 2022
Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash.
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
↗
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
↗
September 02, 2022
Gainers
Via
Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
↗
August 04, 2022
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
↗
September 01, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
